Dr Miguel Perez-Machado
Sonic Healthcare UK welcomes Dr Miguel Perez-Machado, who has joined the team as the Specialty Lead for Diagnostic Cytology.
Dr Perez-Machado is based at the Royal Free London where he is Consultant Histopathologist, and lead for Diagnostic Cytology. He is also Honorary Professor in the Pathology Department at UCLH.
Originally from Cuba, Miguel recognised that the opportunities to do what he wanted there would be limited. It wasn’t easy to leave Cuba, but after jumping through many administrative hoops, he managed to get a place to study in Madrid where he completed his PhD. From Madrid, he came to London, and studied to become a pathologist.
Miguel is passionate about teaching and developing new diagnostic tools in Cytopathology, particularly in areas of pancreas, effusions and thyroid gland.
He is also enthusiastic about living in London (apart from the cold winters) where he enjoys the many cultural attractions on offer. While the Capital is where he feels very much at home, he is also interested in Latin America. It is a region he knows well, and where he is conscious that much of the population does not have access to anything like the advanced medical technologies as those of us in Europe do.
Prof. Manuel Rodriguez-Justo
We also welcome Prof. Rodriguez-Justo, who has joined the HSL Medical Advisory Board as Consultant Specialty Lead for Histopathology. He is a Consultant in Gastrointestinal Pathology and Haematology at UCLH, and Professor of Onco-pathology at UCL-Cancer Institute.
Manuel trained in medicine at Madrid’s Universidad Autonoma, completing his specialisation in Histopathology in Madrid and at the Royal Marsden Hospital.
Manuel originally came to London for three years – and stayed for twenty. Now his home, he enjoys the Capital’s art and music. He enjoys travelling to different countries and is keen to explore the far East.
He says that working within the Sonic Healthcare UK organisation and UCL allows him to extend his research and clinical interests as it gives him greater access to a wide range of new technologies, and highly renowned / world expert teams in cancer biomarkers.